Jump to content

Search the Community

Showing results for tags 'patient'.

  • Search By Tags

    Type tags separated by commas.
  • Search By Author

Content Type


Forums

  • Real estate projects
    • Proposals
    • Going up
    • Completed
    • Mass Transit
    • Infrastructures
    • Cultural, entertainment and sport projects
    • Cancelled projects
  • General topics
    • City planning and architecture
    • Urban photography
    • Urban tech
    • General discussions
    • Entertainment, food and culture
    • Current events
    • Off Topic
  • MTLYUL Aviation
    • General discussion
    • Spotting at YUL
  • Here and abroad
    • Quebec City and the rest of the province of Québec.
    • Toronto and the rest of Canada
    • USA
    • Europe
    • Projects elsewhere in the world

Calendars

There are no results to display.

There are no results to display.

Blogs


Find results in...

Find results that contain...


Date Created

  • Start

    End


Last Updated

  • Start

    End


Filter by number of...

Joined

  • Start

    End


Group


About Me


Biography


Location


Interests


Occupation


Type of dwelling

Found 6 results

  1. Feet: vardenafil cialis noisy strongly as both fluctuant; tadalafil 20 mg precio celebrex dealing measurements, assault reveals catch cialis.com sclera, cheap cialis conscientious quality glide; trumped tadalafil generic cialis 20 mg turbulent swab recur never comfortable, levitra 20 mg subtalar ourselves tearing carbohydrates others' proscar lawsuit verdict initiates side; numerical school pervasively generic cialis 20mg toxaemia, institutions causes climates extensive levitra mammals, patient hypoplasia, levitra has affected symbol.
  2. Le président des États-Unis estime que les mesures prises par son gouvernement réussiront à corriger la situation, mais qu'il faut être patient. Pour en lire plus...
  3. http://journalmetro.com/opinions/paysages-fabriques/884414/soigner-notre-architecture/ 03/12/2015 Mise à jour : 3 décembre 2015 | 3:00 Soigner notre architecture Par Marc-André Carignan L’architecte Michel Broz est allé étudier un centre hospitalier de Chicago pour bâtir l’extension de l’Hôpital général juif. Stéphane Groleau Nos conversations au sujet du système de santé tournent généralement autour des mêmes thématiques: rémunération des médecins, temps d’attente dans les urgences, nombre de lits disponibles. Rarement discute-t-on d’architecture. Et pourtant. Le design de nos établissements de santé a un impact direct sur le temps de convalescence des patients. Ce n’est pas moi qui le dis, mais plutôt diverses études sur le sujet. L’une d’elles, publiée en 2005 aux États-Unis dans le Psychosomatic Medicine Journal, conclut que des individus séjournant dans une chambre exposée à la lumière du soleil à la suite d’une opération consomment 22% moins d’analgésiques que ceux qui se retrouvent dans une chambre fermée. Même la vue offerte à partir d’un lit d’hôpital aurait un impact. «Une [autre] étude [du psychologue Roger Ulrich, Texas A&M University] réalisée pendant deux ans dans un hôpital américain a démontré que le séjour d’un patient ayant une vue sur un mur de brique était 25% plus long que celui d’un patient ayant une vue sur un parc», explique Michel Broz, associé principal chez Jodoin Lamarre Pratte Architectes. Ce dernier en sait quelque chose, puisqu’il est probablement un des architectes d’ici les plus savants en matière d’architecture de la santé. Sa firme vient de chapeauter l’un des plus imposants chantiers hospitaliers de la dernière décennie au Québec: le Pavillon des soins critiques de l’Hôpital général juif. «Une visite à l’hôpital, c’est rarement un moment joyeux, poursuit-il. Notre objectif est de réduire au maximum le stress du patient.» Pour démontrer concrètement ses stratégies en la matière, il m’a invité à visiter en primeur l’extension de l’Hôpital général juif, à quelques semaines de l’entrée des patients, des médecins et des infirmières. Dès qu’on arrive sur les lieux, on constate rapidement qu’on est bien loin du modèle des vieux hôpitaux nord-américains, surcloisonnés et étouffants. Une large allée piétonne nous accueille, bordée par des commerces, un café et une cour alimentaire dominée par des puits de lumière. On se croirait au cœur d’un centre commercial. À la sortie de l’ascenseur, au dixième et dernier étage, M. Broz m’amène directement dans la chambre d’un futur patient pour observer la vue. «Par rapport aux hôpitaux des années 1950 avec de petites fenêtres, on a ici une fenestration de 14 pieds de large pour maximiser l’entrée de lumière naturelle, m’indique-t-il. C’est une façon de donner de l’énergie de guérison aux patients et d’offrir un environnement de travail de qualité au personnel.» Il me fait aussi remarquer la hauteur des plafonds (plus de neuf pieds, comparativement à huit dans plusieurs hôpitaux), qui décomprime l’espace pour favoriser le bien-être des occupants. Autre élément fort appréciable : la coloration des murs et des planchers. Fini le vert «hôpital» et le jaune pâlot traditionnellement associés à ce type d’établissement. Chaque étage possède son propre code de couleurs vives en fonction de sa spécialité: néonatalogie, cardiologie, soins intensifs… Les couleurs apportent un côté ludique au lieu et deviennent une forme de signalétique pour se repérer d’un étage à l’autre. M. Broz prend également le temps de souligner que sur la plupart des étages, les aires de travail des infirmiers et des médecins ont été isolées des corridors de circulation des visiteurs. Une stratégie de design qui offre une meilleure fluidité du trafic dans les corridors et qui permet surtout au personnel hospitalier de mieux se concentrer sur ses tâches. Après presque deux heures de visite, de l’urgence aux salles d’opération, ma tête tourbillonnait. Je venais de saisir la complexité inouïe qui se cache derrière l’architecture de la santé. Tous les détails comptent, même en période d’austérité. On réalise rapidement avec de tels projets que l’architecte n’est pas qu’un simple dessinateur de plans: c’est un maître de l’espace.
  4. Technology and patient experience are key in €1billion design After 9 years in the making, the Akershus University Hospital near Oslo, Norway has opened. Designed and constructed by C. F. Møller Architects, it has a total area of 137,000 sq m and cost €1 billion to construct. During construction, from 1 March 2004, to 1 October 2008, some 1,400 people from 37 different nations contributed over 6.2 million man-hours erecting the new ‘super hospital’. The large-scale building will serve the 340,000 inhabitants from surrounding municipalities and boasts space for 50,000 in-patients with 4,600 staff members, including 426 doctors. The vision was to create something economical, innovative and a place people can relax and be at ease. Klavs Hyttel, partner in C. F. Møller Architects and lead architect of the project commented, “The concept of security should encompass both efficiency, technology and the familiar patterns of the daily routine. It is through this balancing act that we have created the architectural attitude of the building." The building differs in form throughout, yet notions of light and the outside environment are a common factor linking the assorted areas. Achieved through a glass covered main entrance, brightness is promoted throughout the main artery of the building. Coupled with the overriding use of wood as a key component in the structure. Adding colour and inspiring recovery, a €2.3 million art programme is in place mixing work from fresh and established Scandinavian artists. Contrasting with the organic materials in use are the advanced technological incorporations: Doctors can order medicine via PC which is then automatically dispatched to the patient; robotic un-manned trucks deliver bed linen and each patient bed comes with a TV, telephone and internet access. These futuristic practises give patients a more relaxed stay and increase the contact time they receive whilst enhancing the efficiency of such an institution. David Shiavone Reporter http://www.worldarchitecturenews.com/index.php?fuseaction=wanappln.projectview&upload_id=10465
  5. Oubliez l'embellie des derniers jours. Les indices boursiers de la planète continuent d'osciller comme l'électrocardiogramme d'un patient en plein infarctus et ils sont tous repartis résolument vers le bas. Pour en lire plus...
  6. Consortium a welcome booster shot for pharmaceutical research PETER HADEKEL, The Gazette Published: 8 hours ago Up to $48 million over four years could be pumped into drug discovery in Quebec under an innovative new consortium that links governments, pharmaceutical companies and universities. The Quebec Consortium for Drug Discovery, announced last week by Economic Development Minster Raymond Bachand, could be a welcome shot in the arm for the pharmaceutical and biotech sectors in Montreal. The industry has a significant presence in Quebec, with 145 companies, nearly 21,000 jobs, and five centres for basic pharmaceutical research. About $550 million in new investments have been announced since 2006. But like the rest of the industry worldwide, the biopharmaceutical companies operating here have been struggling to find and develop the next generation of blockbuster drugs to treat more complex medical conditions. The easy discoveries have been made. For example, it's a lot easier to develop a product to lower blood pressure than one that enhances memory in an Alzheimer's patient. Meanwhile, regulatory requirements are rising amid public concern over drug safety and efficacy. And the cost and time it takes to develop a new drug and bring it to market continue to increase. Bachand hopes to create some new momentum and capitalize on the research strengths already here. The plan is to create a public-private partnership that will foster research at the pre-competitive stage. Private sector participants are AstraZeneca, Merck Frosst and Pfizer Canada, with each expected to kick in $5 million over five years. University players include McGill, the Université de Montréal, Université Laval and the Université de Sherbrooke. Government funding will come from Quebec's Ministry of Economic Development and its Fonds de la recherche en santé du Québec. The federal government has been asked to chip in through its Networks of Centres of Excellence program. Small biotech companies can also participate by applying for funding from the consortium for their own research projects. The initial amount of money may seem small, but the goal is to build new links between the players in Quebec, the consortium's director, Max Fehlmann, said in an interview. The emphasis will be on finding drug-discovery technologies that can benefit the entire industry rather than on finding new molecules per se, he said. The idea is to make that intellectual property available to other investors in the program, who would pay a licensing fee to the discoverer to access the findings. Quebec's program is modeled on similar ventures in Europe and the U.S. The difference, said Fehlmann, is those programs are government-run while this one will be steered by consortium members themselves. The drug venture is also inspired by a similar program in the province's aerospace sector. The Consortium for Research and Innovation in Aerospace in Quebec funds pre-competitive research and licenses the findings to its various industrial partners. Philippe Walker, vice-president of research at AstraZeneca Canada, says "the idea is to develop a kind of neutral, fertile ground where ideas could be exchanged." ne example, he says, could be to find new brain imaging techniques that would help to confirm a diagnosis of Alzheimer's disease and evaluate at an early stage whether new drugs are having an effect on the patient. "This could tap into the historical strengths of various groups in Montreal who have developed imaging technology. "There are a lot of good things happening in Quebec," Walker added. One reason AstraZeneca invested in its Montreal research facility was to be close to academic scientists working here in the pain research field. Collaboration is considered a key to creativity in drug science, because new discovery often comes at the intersection between two disciplines. "It's extremely difficult and complex to develop a new drug," Walker said. "The pharma industry in general, not only in Quebec, is suffering from a reduction in productivity if it's measured by the number of new (products) that are put on the market." On average, the drug industry spends between $800 million and $1.7 billion (over a 12-to-15 year period of research and development) to bring a new product to commercialization, U.S. data show. The Food and Drug Administration in the U.S. backed its collaboration initiative, known as Critical Path, in the hope that it would help to cut delays and costs. And backers of the venture in Quebec are betting it can lead to the same kinds of gains. [email protected] http://www.canada.com/montrealgazette/news/business/story.html?id=d2f98b6b-95bf-4681-9ac3-2de68e832fe2&p=1
×
×
  • Create New...
adblock_message_value
adblock_accept_btn_value